BRISBANE, Calif., May 25, 2016 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTC:KBIOQ), a development stage biopharmaceutical company focused on advancing treatments for neglected diseases, today announced that Cameron Durrant, MD, chairman and CEO, will present how the company’s Responsible Pricing Model can make a transformative impact, during the International Society for Neglected Tropical Diseases Diagnostics, Drug Discovery & Development Conference in London, UK, May 25-26, 2016.

Dr. Durrant will also participate in a separate panel discussion on treatments for Chagas disease alongside significant global leaders in neglected disease research. KaloBios is working to advance benznidazole for potential US approval to treat Chagas disease and to improve access to this essential medicine.

“We are committed to helping shape transformational change in the world of medicines, with our Responsible Pricing Model as just the beginning,” said Dr. Durrant. “We seek to encourage and engage in open-minded dialogue with stakeholders and are grateful to be part of the ISNTD effort to address critical issues in neglected tropical diseases.”

Details of the presentation and discussion panel are as follows:

Title:Pricing & incentivisation blueprints for the future
Date: Wednesday, May 25, 2016, 10:30 a.m. BST
Participants: Dr. Cameron Durrant, KaloBios Pharmaceuticals; Dr. Laura Fregonese, European Medicines Agency

Title:Chagas disease and strategies for disease-specific treatments
Date: Wednesday, May 25, 2016, 3:45 p.m. BST
Participants: Dr. Eric Chatelain, DNDi; Pr. Simon Croft, London School of Hygiene & Tropical Medicine; Dr. Brigitte Dacosta, bioMérieux; Dr. Julio Martin, GSK; Dr. Cameron Durrant, KaloBios Pharmaceuticals
Chair: Roxanne Khamsi, Nature Medicine

For more information on the conference, please visit www.isntdd3.com.

About KaloBiosPharmaceuticals, Inc.

KaloBios Pharmaceuticals, Inc. (OTC:KBIOQ) is a developmental stage, biopharmaceutical company focused on advancing treatments for neglected diseases. On Dec. 29, 2015, KaloBios filed a voluntary petition for bankruptcy protection under Chapter 11 of Title 11 of the United States Bankruptcy Code, and currently manages and operates its business and assets as a "debtor-in-possession.” KaloBios is working to emerge from bankruptcy.

Forward-Looking Statements

This release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, Bankruptcy Court approval for the Company to continue its operations; the Company’s ability to manage expenses and fund its working capital needs during the Chapter 11 process; the Company’s ability to manage its relationships with its creditors, vendors, and customers during the Chapter 11 process; the Company’s ability to emerge from bankruptcy successfully; the Company’s access to limited cash reserves and its ability to obtain additional capital on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that the Company has initiated or plans to initiate; the potential timing and outcomes of clinical studies of benznidazole, lenzilumab, KB004 or any other products undertaken now or in the future; the Company’s ability to consummate the acquisition of rights to benznidazole; the commercial viability of the Company’s proposed drug pricing program; the ability of the Company to timely source adequate supply of its development products from third party manufacturers on whom the Company depends; the potential, if any, for future development of any of its present or future products; the Company's ability to successfully progress, partner or complete further development of its programs; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; the Company's ability to protect the Company's intellectual property; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and other factors listed under "Risk Factors" in the Company's most recent quarterly report on Form 10-Q filed with the Securities and Exchange Commission on August 10, 2015, the Annual Report on Form 10-K filed on March 16, 2015, and the Company's other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The company has no obligation, and expressly disclaims any obligation to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.

Media Contact:

Lisa Guiterman
(202) 330-3431 (cell)
(301) 217-9353 (office)
media@kalobios.com